Efficacy of adding glutazone to the maximum dose of glibenclamide and metformin resistant on type 2 diabetic patients

Background: to evaluate the efficacy of adding the glutazone to maximum dose of sulfonylurea and metformin in patients with poorly controlled type 2 diabetes. methods: ninety six patients with type 2 diabetes who had failed medical therapy with maximal-dosage of metformin and glibenclamide received glutazone. fasting blood sugar (fbs), 2 hours postprandial (2hpp) glucose, hemoglobin a1c, cholesterol and hdl levels were assessed at baseline three months later. results: ninety-six patients with type 2 diabetes (74 women and 22 men) with the mean age of 55.7±9.9 years were studied. significant reduction was seen in fasting blood sugar (fbs), 2 hours postprandial (2hpp) glucose, hemoglobin a1c and triglyceride levels three months after adding glutazone to therapeutic regimen (p<0.0005). there was not a significant rise in cholesterol and hdl levels before and after the new therapy. conclusion: the results show that the combination of glutazone, metformin and glibenclamide may result in better control of glycemic status in diabetic patients resistant to oral first-line agents.